enVVeno Medical (NVNO)
(Delayed Data from NSDQ)
$4.77 USD
-0.05 (-1.04%)
Updated May 31, 2024 04:00 PM ET
After-Market: $4.78 +0.01 (0.21%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NVNO 4.77 -0.05(-1.04%)
Will NVNO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for NVNO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NVNO
enVVeno (NVNO) Plans to Expedite enVVe Development for CVI
NVNO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for NVNO
enVVeno Medical reports Q1 results
NVNO Stock Earnings: enVVeno Medical Beats EPS for Q1 2024
enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update
enVVeno Medical presents topline efficacy data from SAVVE trial
enVVeno Medical’s VenoValve Trial Shows Promising Results